1Food and Drug Administration, HHS. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labe- ling controls. Final rule[J]. Fed Regist, 2012, 77 (54) . 16158-16163.
2Jackman M, Woods K. An overview of the European Union's new medicines legislation [J]. Int J Pharm Med, 2006, 20(4) :251-261.
4Cerreta F,Eichler HG, Rasi G. Drug policy for anaging population-the European Medicines Agency's geriatric medicines strategy[J. N Engl J Med, 2012,367(21): 1972-1974.
5Sahoo N, Choudhury K, Manchikanti P. Manufacturing of biodrugs., need for harmonization in regulatory standards[-J]. BioDrugs, 2009, 23(4); 217-229.
6Maggioni AP, Dame B, Atar D, et al. FDA and CPMP rulings on subgroup analyses[J-I, Cardiology, 2007107(2) . 97-102.
7Mor6nas J. PICAS: pharmaceutical inspection coopera- tion schemeD-]. Ann Pharm Fr, 2009, 67(1) : 16-19.
9Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic dugs. the International Conference on Harmonization of Technical Requirements for Reg- istration of Pharmaceuticals for Human Use El4 guide- line[-J. J Clin Pharmacol, 2006, 46(5) .498-507.
7The European Parliament and the Council of the European Union, Directive 2001/83/EC On the Community Code Relating to Medidnal Products For Human Use, 6, Artide 40 [S] .Nov, 2001.
8Conduct of Inspections of Pharmaceutical Manufacturers [S]. 20 Sep, 2006.
9Coordination of Pre-approval GxP Inspection[S]. 27 April, 2007.
2Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care [ J ]. Am J Hosp Pharm, 1990,47 (3) :533 -543.
3Christensen DB, Fan'is KB. Pharmaceutical care in commu- nity pharmacies: practice and research in the US[J]. Ann Pharmaeother, 2006,40 (7 - 8 ) : 1400 - 1406.
4Alexander KM, Divine HS, Hanna CR, et at. Implementa- tion of personalized medicine services in community phar- macies : Perceptions of independent community pharmacists [J]. J Am Pharm Assoc, 2014, 54(5) :510-517.
5Evans RG. Waste, economists and American healthcare [J]. Health Policy, 2013,9(2) :12 -20.
6Horvat N, Koder M, Kos M. Using the simulated patient methodology to assess paracetamol - related counselling for headache[J]. PLoS One, 2012, 7(12):e52510.
7Svarsted BL, Bultman DC, Mount JK, et al. Evaluation ofwritten prescription information provided in community pharmacies : a study in eight states [ J ]. J Am Pharm As- soc ,2003,43:383 - 393.
8Roughead L, Semple S, Vitry AI. Pharmaceutical care services : a systematic review of published studies, 1990 - 2003, examining effectiveness to improve patient outcomes [J]. Inter J Phann Pratt, 2005,13:53 -70.
9Cheng Y, Raisch DW, Borrego ME, et al. Economic, clin- ical, and humanistic outcomes (ECHOs) of pharmaceutical care services for minority patients : a literature review[ J ]. Res Social Adm Pharm, 2013,9(3) :311 -329.
10Vogler S, Habimana K, Arts D. Does deregulation in com- munity pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine Euro- pean countries [ J ]. Health Policy, 2014, 117 ( 3 ) : 311 - 327.
